Chronic Lymphocytic Leukemia Treatment Guidelines

Introduction to CLL Treatment

• The optimal treatment for CLL depends on disease stage, patient fitness, and genetic risk factors, with BTK inhibitors and venetoclax-based regimens now preferred over traditional chemoimmunotherapy for most patients to improve survival outcomes, as recommended by the European Society for Medical Oncology 1

First-Line Treatment

• BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) are the preferred first-line therapy due to their effectiveness in high-risk populations, according to the European Society for Medical Oncology 1
• For IGHV-mutated disease, venetoclax plus obinutuzumab (time-limited therapy) or FCR (fludarabine, cyclophosphamide, rituximab) is recommended, as suggested by the European Society for Medical Oncology 1
• For IGHV-unmutated disease, BTK inhibitors (continuous therapy) or venetoclax-based regimens (time-limited) are preferred, as recommended by the European Society for Medical Oncology 1
• For older/less fit patients, venetoclax plus obinutuzumab or BTK inhibitors are recommended, according to the European Society for Medical Oncology 1
• For very frail patients with renal insufficiency, reduced-dose therapy or chlorambucil monotherapy is suggested, as recommended by the European Society for Medical Oncology 2

Relapsed or Refractory Disease

• If relapse occurs >12 months after initial therapy, consider repeating first-line treatment, as recommended by the European Society for Medical Oncology 1, 2, 3
• If relapse occurs <12 months or disease is refractory, switch to alternative therapy class, as suggested by the European Society for Medical Oncology 1, 3, 2
• After BCR inhibitor failure, venetoclax-based therapy is preferred, according to the European Society for Medical Oncology 1
• For high-risk relapsed disease, consider allogeneic stem cell transplantation, which remains the only potentially curative option, as recommended by the European Society for Medical Oncology 1, 2 and the National Comprehensive Cancer Network 4

Autoimmune Complications

• First-line treatment for autoimmune complications is corticosteroids, as recommended by the European Society for Medical Oncology 1, 3
• Second-line treatment is rituximab alone or with cyclophosphamide and dexamethasone, according to the European Society for Medical Oncology 1
• For resistant cases, BTK inhibitors or treatment of underlying CLL is suggested, as recommended by the European Society for Medical Oncology 1

Supportive Care

• Pneumococcal and seasonal influenza vaccination is recommended, as suggested by the European Society for Medical Oncology 1, 3
• Systemic immunoglobulin replacement is only recommended for severe hypogammaglobulinemia with recurrent infections, according to the European Society for Medical Oncology 1, 3
• Antibiotic prophylaxis is recommended for high-risk patients, as suggested by the European Society for Medical Oncology 1, 3

Monitoring and Follow-Up

• Regular physical examination and blood counts are recommended, as suggested by the European Society for Medical Oncology 1
• Bone marrow biopsy and minimal residual disease (MRD) assessment are recommended for complete remission evaluation in clinical trials, according to the European Society for Medical Oncology 1
• CT scans may be helpful but not mandatory outside clinical trials, as recommended by the European Society for Medical Oncology 1
• Blood cell counts should be monitored once weekly during the first weeks of therapy, then every 1-2 months, as recommended by the National Comprehensive Cancer Network 4

Key Recommendations

• Don't delay treatment when patients meet criteria for active disease, as recommended by the European Society for Medical Oncology 1
• Don't use chemoimmunotherapy in patients with del(17p) or TP53 mutations, according to the European Society for Medical Oncology 1
• Don't neglect monitoring for treatment-related complications (cardiac issues with BTK inhibitors, tumor lysis syndrome with venetoclax), as suggested by the European Society for Medical Oncology 1
• Don't overlook infectious complications which are common in CLL patients, as recommended by the European Society for Medical Oncology 1
• The standard approach for early-stage disease without symptoms is a watch and wait strategy with blood count monitoring every 3 months, as recommended by the European Society for Medical Oncology 2
• Allogeneic stem cell transplantation is the only curative treatment and should be considered for younger patients, especially those with unfavorable risk factors, according to the National Comprehensive Cancer Network 4 and the European Society for Medical Oncology 4
• Treatment is indicated when ANY of the following are present: progressive marrow failure, massive/progressive/symptomatic splenomegaly, massive/progressive/symptomatic lymphadenopathy, progressive lymphocytosis, autoimmune complications, symptomatic extranodal involvement, or disease-related symptoms, as recommended by the European Society for Medical Oncology 1
• Chronic Lymphocytic Leukemia (CLL) is defined by ≥5 × 10^9/L monoclonal B cells with characteristic immunophenotype, while Monoclonal B-cell Lymphocytosis (MBL) has a similar phenotype to CLL but with <5 × 10^9/L B cells 1, 5, 3, 2